IL140888A0 - Pharmaceutical compositions comprising peptides for immune neuroprotection - Google Patents

Pharmaceutical compositions comprising peptides for immune neuroprotection

Info

Publication number
IL140888A0
IL140888A0 IL14088801A IL14088801A IL140888A0 IL 140888 A0 IL140888 A0 IL 140888A0 IL 14088801 A IL14088801 A IL 14088801A IL 14088801 A IL14088801 A IL 14088801A IL 140888 A0 IL140888 A0 IL 140888A0
Authority
IL
Israel
Prior art keywords
peptides
pharmaceutical compositions
neuroprotection
immune
immune neuroprotection
Prior art date
Application number
IL14088801A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Priority to IL14088801A priority Critical patent/IL140888A0/xx
Priority to CA002434567A priority patent/CA2434567A1/en
Priority to PCT/IL2002/000032 priority patent/WO2002055010A2/en
Priority to US10/466,220 priority patent/US20040192588A1/en
Priority to JP2002555747A priority patent/JP2005504716A/ja
Priority to IL15690202A priority patent/IL156902A0/xx
Priority to EP02715690A priority patent/EP1572064A4/en
Priority to MXPA03006255A priority patent/MXPA03006255A/es
Publication of IL140888A0 publication Critical patent/IL140888A0/xx
Priority to US11/563,630 priority patent/US20080279869A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL14088801A 1998-05-14 2001-01-14 Pharmaceutical compositions comprising peptides for immune neuroprotection IL140888A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL14088801A IL140888A0 (en) 2001-01-14 2001-01-14 Pharmaceutical compositions comprising peptides for immune neuroprotection
CA002434567A CA2434567A1 (en) 2001-01-14 2002-01-14 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
PCT/IL2002/000032 WO2002055010A2 (en) 2001-01-14 2002-01-14 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
US10/466,220 US20040192588A1 (en) 2001-01-14 2002-01-14 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
JP2002555747A JP2005504716A (ja) 2001-01-14 2002-01-14 神経再生を促進し神経変性を防止するための修飾ｃｎｓ由来ペプチドを含む医薬組成物
IL15690202A IL156902A0 (en) 2001-01-14 2002-01-14 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration
EP02715690A EP1572064A4 (en) 2001-01-14 2002-01-14 PHARMACEUTICAL COMPOSITIONS COMPRISING MODIFIED CNS-DERIVED PEPTIDES FOR PROMOTING NERVE REGENERATION AND PREVENTING NERVOUS DEGENERATION
MXPA03006255A MXPA03006255A (es) 2001-01-14 2002-01-14 Composiciones farmaceuticas que comprenden peptidos derivados del sistema nervioso central modificados para promover regeneracion de nervios y prevencion de degeracion de nervios.
US11/563,630 US20080279869A1 (en) 1998-05-14 2006-11-27 Method for reducing neuronal degeneration by administering cns-derived peptides or activated t cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14088801A IL140888A0 (en) 2001-01-14 2001-01-14 Pharmaceutical compositions comprising peptides for immune neuroprotection

Publications (1)

Publication Number Publication Date
IL140888A0 true IL140888A0 (en) 2002-02-10

Family

ID=11075034

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14088801A IL140888A0 (en) 1998-05-14 2001-01-14 Pharmaceutical compositions comprising peptides for immune neuroprotection

Country Status (7)

Country Link
US (2) US20040192588A1 (xx)
EP (1) EP1572064A4 (xx)
JP (1) JP2005504716A (xx)
CA (1) CA2434567A1 (xx)
IL (1) IL140888A0 (xx)
MX (1) MXPA03006255A (xx)
WO (1) WO2002055010A2 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197561A1 (en) * 2004-03-05 2005-09-08 Elsinger Catherine L. System for detecting symptoms, determining staging and gauging drug efficacy in cases of Parkinson's disease
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP2323696B1 (en) * 2008-09-18 2018-09-05 Cedars-Sinai Medical Center Optical method for the detection of alzheimer's disease
US20110124706A1 (en) * 2009-11-25 2011-05-26 Zhigang He SOCS3 Inhibition Promotes CNS Neuron Regeneration
EP2773382A4 (en) 2011-11-01 2016-03-23 Childrens Medical Center CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION
WO2014037952A1 (en) * 2012-09-10 2014-03-13 Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
CA1341050C (en) * 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US5633426A (en) * 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5837223A (en) * 1996-08-12 1998-11-17 Revlon Consumer Products Corporation Transfer resistant high lustre cosmetic stick compositions
US6319892B1 (en) * 1997-07-18 2001-11-20 Ralf Gold Use of recombinant myelin protein for treating T-cell-mediated autoimmune diseases of the peripheral nervous system
EP1039929A1 (en) * 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses

Also Published As

Publication number Publication date
US20080279869A1 (en) 2008-11-13
WO2002055010A2 (en) 2002-07-18
WO2002055010A3 (en) 2005-07-28
JP2005504716A (ja) 2005-02-17
CA2434567A1 (en) 2002-07-18
EP1572064A2 (en) 2005-09-14
MXPA03006255A (es) 2003-09-22
US20040192588A1 (en) 2004-09-30
EP1572064A4 (en) 2006-12-06

Similar Documents

Publication Publication Date Title
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
IL227966A0 (en) Vaccination kit
GB0319041D0 (en) Pharmaceutical Formulations
GB0103170D0 (en) Vaccine composition
IL158297A0 (en) Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
PL370669A1 (en) Pharmaceutical composition
GB0121715D0 (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
GB0116107D0 (en) Pharmaceutical composition
IL140888A0 (en) Pharmaceutical compositions comprising peptides for immune neuroprotection
GB0104752D0 (en) Pharmaceutical compositions
GB0127805D0 (en) Pharmaceutical composition
GB2382302B (en) Pharmaceutical compositions
IL157411A0 (en) Pharmaceutical composition
GB0124455D0 (en) Pharmaceutical formulations
GB0126732D0 (en) Pharmaceutical compositions
IL136274A0 (en) Pharmaceutical compositions comprising vip-related peptides
IL138971A0 (en) Pharmaceutical compositions comprising vip-related peptides
HU0103049D0 (en) Pharmaceutical composition
GB0101058D0 (en) Pharmaceutical compositions
GB0101743D0 (en) pharmaceutical compositions
GB0101744D0 (en) Pharmaceutical compositions